Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not express estrogen receptor, progesterone receptor, or HER2. TNBC has high mitotic activity, and since Aurora A and B mitotic kinases drive cell division and are overexpressed in tumors with a high mitotic index, we hypothesized that inhibiting Aurora A and B produces a significant antitumor effect in TNBC. We tested this hypothesis by determining the antitumor effects of KW-2450, a multikinase inhibitor of both Aurora A and B kinases. We observed significant inhibitory activities of KW-2450 on cell viability, apoptosis, colony formation in agar, and mammosphere formation in TNBC cells. The growth of TNBC xenografts was significantly inhibited with KW-2450. In cell cycle analysis, KW-2450 induced tetraploid accumulation followed by apoptosis or surviving octaploid (8N) cells, depending on dose. These phenotypes resembled those of Aurora B knockdown and complete pharmaceutical inhibition of Aurora A. We demonstrated that 8N cells resulting from KW-2450 treatment depended on the activation of mitogen-activated protein kinase kinase (MEK) for their survival. When treated with the MEK inhibitor selumetinib combined with KW-2450, compared with KW-2450 alone, the 8N cell population was significantly reduced and apoptosis was increased. Indeed this combination showed synergistic antitumor effect in SUM149 TNBC xenografts. Collectively, Aurora A and B inhibition had a significant antitumor effect against TNBC, and this antitumor effect was maximized by the combination of selumetinib with Aurora A and B inhibition.
Introduction
Triple-negative breast cancer (TNBC), which is negative for estrogen receptor (ER), progesterone receptor, and HER2, is clinically and biologically distinct from the other breast cancer subtypes (e.g., ER+, HER2+ breast cancer) (1, 2) . From a clinical standpoint, TNBC is one of the most aggressive forms of breast cancer because of its early relapse behavior, high propensity for metastasis, and refractoriness to multiple anticancer drugs. Patients with TNBC cannot be treated with anti-estrogen agents (e.g., tamoxifen, aromatase inhibitors) or anti-HER2 agents (e.g., trastuzumab) because of the lack of expression of ER, progesterone receptor, and HER2. Currently, no molecularly targeted drug is available that has shown a benefit in TNBC (3) ; therefore, such a drug needs to be developed. Aurora A and Aurora B are mitosis-related serine/threonine kinases that are overexpressed or genetically amplified in a significant percentage of various tumor types including TNBC (4, 5) . A growing number of studies support the development of Aurora A/B inhibitors as anticancer drugs (6) (7) (8) . Physiologically, Aurora A plays a critical role in centromere duplication and maturation throughout the late G2 to mitotic phases; therefore, Aurora A inhibition delays initiation of mitosis, which in turn causes mitotic accumulation and activates the spindle assembly checkpoint (SAC) (4, 9) . In contrast, Aurora B secures the integrity of chromosome segregation at the SAC during metaphase. Between anaphase and telophase, Aurora B executes cytokinesis. Therefore, Aurora B inhibition causes inactivation of the SAC and accelerates mitotic-slippage by destabilizing the cytokinetic process (10) (11) (12) . Thus, either Aurora A or Aurora B inhibition could evoke cell death at the SAC or after mitotic-slippage (e.g., at the postmitotic G1 checkpoint), respectively, in cancer cells (13, 14) .
We previously revealed the tumor suppressive functions of the SAC and postmitotic G1 checkpoint by using cancer cell lines and a transgenic mouse tumor model (15) (16) (17) . In cultured cell line models, we showed that the SAC was indispensable to induce apoptosis of MCF7 cells with paclitaxel and that the SAC functioned independently from the G2 checkpoint (15); we further showed that the SAC induced mitotic cell death in p53-null HCT116 colon cancer cells treated with cisplatin (16) . With use of a mouse mammary pre-neoplastic model, we showed that perturbation of Aurora A function (i.e., overexpressed Aurora A) activated the postmitotic G1 checkpoint and inhibited the transformation to lethal tumors (17) . On the basis of these experimental findings, in addition to the clinical significance of Aurora A/B kinases (4-6), we reasoned that we could develop an Aurora A/B inhibitor against TNBC, exploiting the SAC and/or postmitotic G1 checkpoint of TNBC cells. To this end, in the present study we used KW-2450, a multikinase inhibitor that exhibits more robust inhibitory activities against Aurora A and Aurora B, and tested its antitumor effects in vitro and in vivo (18) .
We here show that KW-2450 induced cell death in vitro and produced antitumor effects in vivo in a type of TNBC cells (i.e., MDA-MB-468). In contrast, other TNBC cells (i.e., MDA-MB-231, SUM149 cells) were relatively resistant to KW-2450-induced cell death, escaping from the SAC and postmitotic G1 checkpoints, and interestingly entered into the octaploid (8N) phase. We were able to attribute these phenotypes to the inhibition of Aurora A and B. We further discovered that survival of the 8N cells depended on the activation of the mitogenactivated protein kinase kinase (MEK) pathway and that these cells were therefore killed when treated with the MEK inhibitor selumetinib combined with KW-2450. We here propose Aurora A/B inhibition and Aurora A/B inhibition combined with MEK inhibition as promising therapeutic approaches in TNBC. Cancer Center by using a short tandem repeat method. For all cell lines, TP53 mutation status is available in Supplementary Table S1 .
Materials and Methods

Cell lines
Drugs
KW-2450 was provided by Kyowa Hakko Kirin Co., Ltd. (Tokyo, Japan). Selumetinib was purchased from ChemieTek (Indianapolis, IN). Paclitaxel was purchased from the core facility for experimental supplies at The University of Texas MD Anderson Cancer Center.
Western blot analysis
Cell pellets were lysed as described previously (19) . Primary antibodies that we used in this study were rabbit anti-phospho Aurora A (T288), rabbit anti-insulin-like growth factor-I receptor (IGF-IR), rabbit anti-insulin receptor (InsR) β, rabbit anti-phospho-IGF-IR/InsR kinase (Thr202/Tyr204), rabbit anti-extracellular signal-regulated protein kinases (ERKs), rabbit antiphospho-ERKs, rabbit anti-c-Jun N-terminal kinases (JNKs), rabbit anti-phospho-JNKs, rabbit anti-p38, and rabbit anti-phospho-p38 (all from Cell Signaling Technology, Beverly, MA); and mouse anti-Aurora A (BD Biosciences, San Jose, CA), rabbit anti-cyclin B1 (Santa Cruz Biotechnology, Dallas, TX), and mouse anti-β-actin Ab (diluted at 1: 5000; Sigma-Aldrich, St.
Louis, MO). Antibodies were diluted at a ratio of 1:1000, unless noted. Signals were detected with use of an Odyssey IR imaging system (LI-COR, Lincoln, NE).
Immunofluorescence analysis and Aurora A assay
MDA-MB-468 cells were grown on 4-chamber slides (BD Biosciences, San Jose, CA) and treated with DMSO or KW-2450. For immunofluorescent staining, cells were stained with anti-Aurora A pT288 rabbit antibody (1:250) and anti-Aurora A kinase mouse monoclonal antibody (1:250), followed by anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 594 secondary antibodies. DNA was counterstained with DAPI (VECTA STAIN). Fluorescently labeled cells were visualized with a Nikon FV 1000 fluorescent microscope, and images were captured with a digital camera (Nikon). For the Aurora A assay, kinase activities of Aurora A were determined by measuring pT288 fluorescent intensity (Alexa Fluor 488) in the mitotic cells that had bipolar Aurora A spots and presented as the value relative to Aurora A fluorescent intensity (Alexa Fluor 594). A concentration-inhibition curve was generated by calculating the Aurora A kinase activities in KW-2450-treated samples relative to the DMSO-treated control, and the IC 50 for inhibiting Aurora A kinase activity was determined by Prism5 software.
Cell-cycle, mitosis, and Aurora B assays
Cells were plated in 6-cm dishes, cultured for 1-2 days, and then treated with DMSO, KW-2450, or KW-2450 plus selumetinib. In each experiment, DMSO-treated cells were used as the control. Cell-cycle distribution was analyzed by a fluorescence-activated cell sorter (FACS) as described previously (19, 20) . For mitotic analysis, cells were stained with anti-phosphohistone H3 (pHisH3) conjugated with FITC, incubated with RNase (100 µg/mL), and stained with PI (25 µg/mL). For the Aurora B assay, 4N pHisH3+ (FITC+) cells were quantified by FACS to measure the kinase activities of Aurora B in KW-2450 treatments (because histone H3 is a kinase substrate of Aurora B). A concentration-inhibition curve was generated, and the IC 50 for inhibiting Aurora B kinase activity was determined as in the Aurora A assay. were depleted by a proper gating strategy, and singlets were analyzed to determine the percentages of CD44+CD24-and non-CD44+CD24-fractions by using Flowjo software.
Growth inhibition assay in vitro
Colony formation in agar assay
Colony formation in the agar assay was performed as previously described (21) . Briefly, TNBC cells (2 × 10 hours at 37°C, and colony numbers were counted by using GelCount (OXFORD OPTRONIX, United Kingdom).
Mammosphere-forming assay
The mammosphere-forming assay was performed as described previously (22) . Cells were plated into 6-well low-attachment dishes at a density of 2,000 cells/mL. KW-2450 or DMSO was added when cells were plated. Cells were cultured for 4 or 5 days and then incubated with MTT (50-100 µg/mL) for 1 hour before the mammospheres were counted by GelCount.
Animal xenograft studies
All animal experiments were approved by the Institutional Animal Care and Use 
Combinatory drug treatment in vitro
In combinatory treatments with KW-2450, Selumetinib were added at the double concentrations to those of KW-2450 at each concentration point (described as ×2 in Fig. 6B ).
Synergism between KW-2450 and selumetinib in terms of growth inhibition in vitro was determined by CalcuSyn software (BIOSOFT, Cambridge, United Kingdom).
Statistical analyses
Statistical analyses were conducted by R software. Data were presented as means ± s.e.m.
Means for all data were compared by an unpaired t test. P values of <0.05 were considered statistically significant. 
Results
KW-2450 inhibits kinase activities of Aurora A, Aurora B, and IGF-IR at various concentrations
The chemical structure of KW-2450 is shown in Fig. 1A . We first tested KW-2450's inhibitory activity against Aurora A kinase in cell based assay. We measured the inhibitory effect of KW-2450 on Aurora A activity at various concentrations in MDA-MB-468 cells, which was probed with the antibody against Aurora A autophosphorylation on threonine-288 (pT288) (Fig.   1B ). Threonine-288 is an autophosphorylation site of Aurora A and thus a marker of Aurora A activity (4, 13) . To accumulate the cells in the mitotic phase, we pretreated them with paclitaxel at 100 nM as previously described (15) of Aurora B kinase activation (13, 23) . We pretreated the cells with paclitaxel for 20 hours and then treated them with KW-2450 at various concentrations for 4 hours under continuous paclitaxel treatment, and pHisH3-positive (pHisH3+) cells were quantified using FACS analysis (Fig. 1D) . Treatment with KW-2450 at 0.5 and 10 µM reduced pHisH3+ cells, which is indicative of Aurora B inhibition in MDA-MB-468 cells (Fig. 1D) . The concentration and inhibition curve was drawn to determine the potency of KW-2450 against Aurora B kinase activity by quantifying pHisH3+ mitotic cells (Fig. 1E) . KW-2450 inhibited Aurora B within 4 hours with IC 50s of 0.478 µM (95% CI = 0.368-0.620 µM) in MDA-MB-468 cells (Fig. 1E) Fig. S1 ). In both MDA-MB-468 and SUM149 cells, which endogenously overexpressed IGF-IR, KW-2450 (0.002 µM) reduced kinase activities of IGF-IR by about 25% compared with the DMSO control (which showed 100% activity). This indicates that KW-2450's IC 50 for inhibiting IGF-IR in the cell-based assay was less than 0.002 µM.
Taken together, these data suggest that KW-2450 is able to inhibit Aurora A and Aurora B kinases at a higher concentration and IGF-IR kinase at a lower concentration.
KW-2450 shows in vitro antitumor effects in TNBC cells
The effects of KW-2450 on cell viability of TNBC cells were tested by the CellTiter-Blue Cell Viability Assay (Promega Corporation). Concentration-inhibition curves were drawn as We previously showed in TNBC and glioblastoma multiforme mouse models that cancer stem cells (CSCs) have a quiescent trait and overexpress IGF-I, which was a key molecule for making CSCs quiescent in these models (20, 24) . On the basis of these findings, we assumed that letting CSCs exit from the quiescent state and stay in mitosis by inhibiting IGF-IR and Aurora A/B may work as CSC-targeted therapy in TNBC. We therefore treated TNBC cells with KW-2450 at various concentrations and assessed anti-CSC activities of KW-2450 by the following assays: colony formation in agar assay, mammosphere-forming assay, and CD44+CD24-CSC markers labeling assay (22, 24, 25) . KW-2450 dose-dependently inhibited colony formation in agar and mammosphere-forming in floating culture in SUM149 and MDA-MB-231 cells (Fig.   2B, C) . The CD44+CD24-CSC populations were also significantly reduced, depending on the concentrations of KW-2450 in both cell lines (Supplementary Fig. S2 ). Overall, KW-2450 showed antitumor and anti-CSC activities in in vitro cell assays.
KW-2450 induces 4N and 8N accumulations and apoptosis in TNBC cells
The effect of KW-2450 on the cell cycle was evaluated by FACS analysis (Fig. 3A) . In all three TNBC cell types, KW-2450 dose-dependently induced tetraploid (4N), 8N, and subG1 (cell death) phases. It is known that Aurora A inhibition induces the delay in mitotic entry, which causes 4N, and that Aurora B inhibition induces mitotic-slippage, which causes 8N in (9, 10) . Both of these outcomes, 4N or 8N, could cause cell death after all (13, 14) . Based on this evidence, Aurora A and/or B could be primarily inhibited at higher concentrations of KW-2450 (0.5, 1 µM) in TNBC cells. Meanwhile, we tested the significance of inhibiting IGF-IR or InsR using siRNAs in these TNBC cells (Supplementary Fig. S3 ). We then confirmed that neither of the siRNAs to IGF-IR or InsR caused 4N, 8N, and subG1 phenotypes, suggesting that neither IGF-IR nor InsR inhibition is responsible for these phenotypes.
In MDA-MB-468 cells, compared with both MDA-MD-231 and SUM149 cells, we observed more subG1 cells at higher concentrations of KW-2450 (0.5, 1 µM). To determine whether this cell death could be attributed to apoptosis, we performed an Annexin V assay using MDA-MB-468 cells (Fig. 3B, 3C) . We treated MDA-MB-468 cells with 0.5 µM KW-2450 and monitored the amount of Annexin V+ cells undergoing apoptosis during the treatment. The number of Annexin V+ cells substantially increased within 24 to 48 hours of KW-2450 treatment compared with the DMSO control, suggesting ongoing apoptosis (Fig. 3C) .
Reactive oxygen species (ROS) is a key mediator of apoptosis and accumulates in the cells by activation of mitochondrial pathways (26, 27) . We quantified intracellular ROS levels among three types of TNBC cells treated with DMSO or KW-2450 (0.5 or 1 µM). In MDA-MB-468 cells treated with KW-2450, we observed considerably higher accumulation of ROS compared with levels in the DMSO control (Fig. 3D, 3E) . (Fig. 3F) . We chose a concentration of 0.5 µM because we had observed a difference in the rates of apoptosis between MDA-MB-468 cells and the other two cell types (i.e., MDA-MB-231 and SUM149 cells) at this concentration, which we thought could give us insight at a molecular level into the sensitivity to KW-2450. At 12 and 24 hours of KW-2450 treatment, we observed accumulation of 4N in both MDA-MB-468 and MDA-MB-231 cells (Fig. 3F) . At Fig. S4 ). (Supplementary Fig. S6 ), suggesting again that p53 at post-mitotic G1 is a determinant of the 8N phenotype with KW-2450 treatment.
Depletion of Mad2 or
Independent of cell cycle checkpoints, we also sought to determine whether senescence causes resistance to KW-2450 in TNBC cells, as reported by others (28, 29) . We did not see significant senescence induction in any TNBC cells treated with 0.5 µM KW-2450 for 5 days; however, we did see induction of senescence at higher concentrations (1, 4 µM) and with longer exposure to KW-2450 (for 10 days) (Supplementary Fig. S7 ). Collectively, 8N cells caused by KW-2450 (0.5 µM) did not undergo apoptosis or senescence, thus arresting at the 8N phase as surviving cells.
Inhibition of Aurora A and B is responsible for 4N, 8N, and apoptosis caused by KW-2450
Next, by using MDA-MB-468 and MDA-MB-231 cells, we determined which inhibition against Aurora A or Aurora B was mainly responsible for 4N or 8N accumulation coupled with apoptosis. To this end, we performed knockdown experiments using siRNAs to Aurora A or B in MDA-MB-468 and MDA-MB-231 cells (Fig. 4) MDA-MB-231 cells and in a small fraction of 8N in MDA-MB-231 cells (Fig. 4A, B) .
Treatment with Aurora B siRNA also induced a substantial amount of cell death (subG1) in MDA-MB-468 cells but less in MDA-MB-231 cells, whose trend was similar to the one observed in KW-2450 treatment. In contrast, treatment with Aurora A siRNA did not cause significant changes in cell cycle profiles of MDA-MB-468 and MDA-MB-231 cells. However, inhibition of Aurora A is known to cause 4N accumulation; we therefore further inhibited Aurora A kinase by using Aurora A-specific inhibitor MLN8054 in MDA-MB-468 cells (Fig. 4C-E) .
With use of 0.05 and 0.1 µM MLN8054, Aurora A kinase activities were inhibited by about 30% and 0%, respectively (Fig. 4D) , which caused accumulations of 4N and subG1 phases depending on the dose (Fig. 4E) . Especially at 0.1 µM MLN8054, which achieved complete inhibition of Aurora A, MLN8054 dramatically induced accumulation of 4N and subG1 phases. These data suggest that complete inhibition of Aurora A kinase does induce 4N and apoptosis in MDA-MB-468 cells.
In summary, using two types of TNBC cells, we showed that either specific inhibition of Aurora A or Aurora B could cause 4N and/or 8N accumulation and apoptosis in TNBC cells, depending on the type of cells. Therefore, we cannot conclude that inhibition of either Aurora A or Aurora B is responsible for these phenotypes caused by KW-2450, but presumably inhibition of either produces these results.
KW-2450 single treatment inhibits tumor growth of TNBC cells in vivo
We next evaluated in vivo antitumor activity of KW-2450 by using MDA-MB-468 tumors grown as xenografts in nude mice (Fig. 5) . KW (Fig. 5A) . We monitored the body weights of MDA-MB-468 tumor-bearing mice during the treatments and observed that KW-2450-treated mice had 11.5 ± 4.9 (average ± s.e.m.) % more body weight at the end of the KW-2450 treatment compared with vehicle-treated mice, although this difference did not reach statistical significance (Supplementary Fig. S8 ). (Fig. 5C ).
KW-2450 and MEK inhibitor synergize in inducing cell death in TNBC cells
We observed diverse susceptibilities to cell death among cultured TNBC cells treated with 0.5 µM KW-2450 (Fig. 3A, 3F ). As described above, abrogation of p53 can induce 8N accumulation under KW-2450 treatment, which is a resistance phenotype against KW-2450. Table S1 ), we need to overcome this resistance mechanism derived from abrogated p53 in TNBC cells. We focused on mitogen-activated protein kinases (MAPKs) (e.g., ERK1/2, p38 MAPK, JNKs), which are treatment similar to the way in which these MAPK pathways respond to anticancer drugs (30) (31) (32) (33) .
Given TNBC cells frequently have mutated p53 (Supplementary
We first examined the dose effect of KW-2450 on the activation of MAPK pathways by detecting the phosphorylation of ERK1/2, p38 MAPK, and JNKs (Fig. 6A) . We observed activation in ERK1/2 as a result of dose escalation of KW-2450 but not in p38 MAPK or JNKs, suggesting that the activation of MEK1/2 (upstream kinases of ERK1/2) and of ERK1/2 may play a role in protecting TNBC cells treated with KW-2450. To test this hypothesis, we added the MEK1/2 inhibitor selumetinib (34, 35) to KW-2450 in SUM149 and MDA-MB-231 cells and evaluated its synergistic effects by using a cell viability assay and cell cycle analysis (Fig. 6B, C) .
In testing various concentrations, we observed synergism between KW-2450 and selumetinib in terms of cell growth inhibition (Fig. 6B) . This synergism was also observed in the cell cycle analysis. We observed that selumetinib (1 µM) plus KW-2450 (0.5 µM) significantly increased subG1 populations in both MDA-MB-231 and SUM149 cells compared with KW-2450 alone (Fig. 6C) . In parallel, 8N cells were significantly reduced with selumetinib plus KW-2450 compared with KW-2450 alone in both MDA-MB-231 and SUM149 cells. These findings suggest that activated ERK1/2 protects TNBC cells treated with KW-2450 from cell death at an 8N phase.
Finally, we tested whether this synergistic effect would be observed in vivo (Fig. 6D) . To answer this question, we used SUM149 cells, which had shown relative resistance to cell death when treated with KW-2450 alone; cell death was induced in vitro, however, by adding selumetinib onto KW-2450. For treatment with selumetinib, either of 50 or 100 mg/kg per day of selumetinib was used for single and combination therapies with KW-2450 as previously 
showed significant growth inhibition compared with the vehicle-treated group from day 3 through day 28. Furthermore, either of the combination therapies showed significant growth inhibition compared with either matched single treatments throughout the treatment courses.
Discussion
In the present study, we concluded that Aurora A and B were primary targets of KW-2450 in the antitumor effects seen in TNBC. TNBC cell lines relatively resistant to KW-2450 underwent cell death when treated in a combination with the MEK inhibitor selumetinib.
Historically, the development of Aurora kinase inhibitors started with pan-Aurora kinase inhibitors such as VX-680, and several Aurora A/B kinase dual inhibitors followed (7, 8, 27, (36) (37) (38) . The development of Aurora A/B kinase inhibitors led to the recognition that inhibition of Aurora B kinase is mainly responsible for the antitumor effects of Aurora A/B dual kinase inhibitors (6) . KW-2450 is considered a dual Aurora A/B kinase inhibitor, with similar IC 50 values against Aurora A and Aurora B kinases (39) . Consistent with previous studies of dual kinase inhibitors of Aurora A and B (14, 38) , KW-2450 dose-dependently induced 4N, 8N, and apoptosis at various rates, depending on the type of TNBC cells (Fig. 6E) . However, at the highest concentrations (1.0 µM), 8N became the dominant population in all TNBC cells, which is a sign that Aurora B inhibition overtook Aurora A inhibition. Moreover, we observed accumulations of mitotic cells (shown with pHisH3+ or increased cyclin B1), which is a wellknown outcome of Aurora A inhibition, in MDA-MB-468 and SUM149 cells ( Supplementary   Fig. S9) . Therefore, at 0.5 µM KW-2450 we saw growth inhibition or apoptosis in TNBC cells (Fig. 2, 3) , and inhibition of both Aurora A and B could be contributing to these antitumor effects in vitro. Since specific inhibitors to Aurora A and B are under development, testing all of these compounds may reveal further molecular background into the diverse responses to KW-2450 treatment, such as 8N accumulation or apoptosis.
Our finding of the tumor inhibitory effects of KW-2450 according to the subtype of breast cancer was also of interest. We showed that IC 50 values for inhibiting cell viability in 
TNBC were higher than those for ER+ breast cancer. This finding suggests two possibilities: 1) ER+ breast cancer cells are more sensitive to Aurora A and B inhibition than are TNBC cells, or 2) targeted kinases other than Aurora A and B are responsible for these lower IC 50 values in ER+ breast cancer. If the latter is the case, IGF-IR could be one such targeted kinase in ER+ breast cancer. In fact, in another study that tested IGF-IR inhibitor NVP-AEW541 for breast cancer cells, MCF7 cells showed the highest sensitivity to IGF-IR inhibition among several breast cancer cells including TNBC cells, which is exactly the same trend that we saw in the present study. These findings, together with our data, suggest that IGF-IR could be a legitimate target in ER+ breast cancer but not in TNBC cells.
In contrast to our conclusion, several studies support targeting of the IGF-IR pathway in TNBC cells. Lee's group initially showed the prognostic significance of the IGF-IR gene signature to predict poor breast cancer prognosis (40) , which was also correlated with the ERnegative subtype. They further developed this concept in a preclinical study. With use of BMS-754807, a dual IGF-IR/InsR inhibitor, they showed the antitumor effects of BMS-754807 in vitro and in vivo (41) . BMS-754807 is a reversible inhibitor to both IGF-IR and InsR, which is very potent with the Ki value of <2 nM. In an IGF-IR kinase inhibitory assay with BMS-754807, a concentration of 3 to 10 nM was enough to reduce IGF-IR kinase activity by less than half of that of the DMSO-treated control, meaning that IC 50 to inhibit IGF-IR kinase activity was less than 3 to 10 nM, which is close to our value for KW-2450 (<2 nM). Despite this potent inhibitory According to the original report of BMS-754807, the 51 top-ranked potential targets included all Aurora kinase family proteins (Aurora A, B, C) and another mitotic kinase, PLK4. These findings, together with our data, suggest that IGF-IR and/or InsR inhibition may not be enough to inhibit the growth of TNBC cells and that other targets need to be inhibited. Among these potential targets, Aurora A and B kinases are the leading candidates to be inhibited to have antitumor effects in the context of TNBC.
In conclusion, we showed the antitumor effects of KW-2450, focusing on Aurora A and B kinase inhibition in TNBC, and discovered a novel combinatorial opportunity with Aurora A/B inhibitor and MEK inhibitor for those cells with less sensitivity to KW-2450 (Fig. 6E) . In the future, we will need to answer the questions "how does the MEK-ERKs pathway get activated in response to Aurora A/B inhibition?" and "Why is there diversity in terms of the response to Aurora A/B inhibition (e.g., activation level of MEK)?" Delineating the molecular background and marker development in regard to this combinatory therapy is worth pursuing in TNBC, which currently does not have any molecularly targeted therapies in a standard care setting. 
